Mantell Associates’ Post

$100 million to develop covalent biologics for oncology ! Enlaza Therapeutics just secured $100 million in Series A funding, led by J.P. Morgan Asset Management’s Private Capital division, to advance its covalent biologic platform for novel protein drugs, particularly in oncology. ⚗️Safer and more tolerable tumor penetration : Enlaza's War-LockTM technology creates biologic drugs that bind irreversibly to disease targets, enhancing efficacy and safety. By promoting covalency, it improves therapeutic performance, reduces systemic exposure, and allows sustained biologic effects with minimal dosing. Using proprietary amino acids, Enlaza engineers precise biological medicines with enhanced properties, offering a versatile solution across different protein-drug formats. 💊Investors : J.P. Morgan led the funding round, joined by existing investors like Frazier Life Sciences and new ones including Amgen and Regeneron's investment arms.

𝗖𝗮𝗻𝗰𝗲𝗿 𝗝𝗮𝗻𝘂𝘀 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟭. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 The research report encompasses an overview of the development of the Cancer Janus Kinase Inhibitors industry chain, focusing on its applications in Hospitals (Ruxolitinib, Momelotinib) and Ambulatory Surgical Centers (Ruxolitinib, Momelotinib). It highlights key enterprises in both developed and developing markets while analyzing cutting-edge technology, patents, hot applications, and market trends of Cancer Janus Kinase Inhibitors. 𝐓𝐨 𝐊𝐧𝐨𝐰 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐜𝐨𝐩𝐞 𝐚𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐨𝐟 𝗖𝗮𝗻𝗰𝗲𝗿 𝗝𝗮𝗻𝘂𝘀 𝗞𝗶𝗻𝗮𝘀𝗲 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/guSqh8-w *𝗕𝘆 𝗧𝘆𝗽𝗲: Ruxolitinib, Momelotinib, Lestaurtinib, Pacritinib, *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Hospitals, Ambulatory Surgical Centers, Others *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Abbott, Asana BioSciences, LLC, AstraZeneca, Celonic Group, Dynamic Pharma S.A. – Δυναμική Φαρμακαποθήκη Α.Ε., Eli Lilly and Company, Gilead Sciences, Hanmi Pharmaceuticals, Incyte, Kyowa Hakko USA, Moleculin Biotech, Inc., Pfizer, Portola Pharmaceuticals #januskinaseinhibitors #cancerresearch #cancertreatment #oncology #drugdevelopment #cancertherapeutics #pharmaceuticals #biomedicalscience #jakinhibitors #precisionmedicine

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Century Therapeutics buys Clade; Eliem announces $120M PIPE and a deal: Plus, news about Leap Therapeutics, Allay Therapeutics, Harmony Biosciences, Rallybio and CSL Behring: Century Therapeutics acquires Clade: Century is purchasing the off-the-shelf cell therapy startup for $35 million upfront in cash and stock in a deal that comes after Clade laid off employees and closed its Dutch subsidiary, as Endpoints News reported in February. Clade launched with $87 million in 2021 and was founded by CRISPR Therapeutics co-founder Chad Cowan. Century also announced that it’s expanding its lead iNK cell therapy into autoimmune disease, beginning with a form of lupus called SLE, and it raised $60 million from a private placement in light of the autoimmune expansion. — Lei Lei Wu Eliem acquires Tenet, plans to advance its lead drug: The company will now focus on TNT119, an anti-CD19 antibody designed to treat autoimmune diseases, including systemic lupus erythematosus. In conjunction with the buyout, Eliem raised $120 million in a PIPE financing, which likely gives the company runway into 2027. Most of Eliem’s board will remain, and Tenet CEO Stephen Thomas has been named interim CEO of the newly combined company. — Max Gelman Leap Therapeutics also announces a PIPE: The oncology biotech sold approximately $40 million in shares to institutional investors including Gilead, Samsara BioCapital, 683 Capital Partners, Laurion Capital Management and Rock Springs Capital. It plans to use the proceeds to fund its lead program, an anti-DKK1 antibody that it’s studying in second-line colorectal cancer. — Lei Lei Wu Allay Therapeutics’ pain drug sails through Ph2b: The biotech said ATX101 achieved sustained post-surgical pain relief for up to four weeks in patients following knee replacement. The non-opioid drug candidate also outperformed the standard of care — bupivacaine — in durability. Allay is planning to start a separate, registrational Phase 2b test later this year. — Ayisha Sharma Harmony Biosciences nabs license for OX2R agonist: Harmony will pay $25.5 million upfront to French pharma company Bioprojet to “develop, manufacture and commercialize” TPM-1116, per a press release. If everything works out, Harmony is also on the hook for up to $357.5 million in development and sales milestones. — Max Gelman MIT-founded DeepCure raises $24M: The company, which has put together about $72 million so far, is calling the raise a “Series A-1″ round. DeepCure researchers are working to develop new small-molecule drugs and identify new targets with the help of artificial intelligence. — Max Gelman Rallybio’s non-traditional deal with J&J: Johnson & Johnson is teaming up with Rallybio, which is developing a “complementary” treatment for a rare disease affecting fetuses and… #lucidquest #genetherapy #celltherapy

What are Wave 3 biologics and why are they attracting little to no biosimilar competition? Wave 3 biologics are the latest wave of complex biologics characterized by rising levels of manufacturing, clinical testing and logistical complexity. This cohort comprises antibody-drug conjugates (ADC), cell and gene therapies (or Advanced Therapy Medicinal Products; ATMPs), oligonucleotides and PD-1 inhibitors. Wave 3 includes products facing LoE (loss of exclusivity) events by 2032. Although not all of these products target rare diseases, a rising share of them do. There are currently no candidates for any of these complex orphan drugs, but there are 16 candidates for non-orphan, Wave 3 biologics. The chart shows the pipeline for these biologics, which includes an early asset (Phase I) referencing trastuzumab emtansine, eight biosimilar candidates for pembolizumab and seven for nivolumab. Yet, not all these candidates are expected to progress to clinical trials or enter the European market following the expiry of patents and other exclusivity rights because of challenges to development and feasibility. IQVIA Institute’s Assessing the Biosimilars Void report further discusses the factors that affect the development and launch of new biosimilars for these complex biologics. Download the report here: https://bit.ly/47nFe3d. #ForecastLink #ArkPatent #IQVIAMIDAS #GlobalHealth #Datascience #Biosimilars

Recent Funding: Marea Therapeutics (SF) has emerged with $190 million and a mid-stage #cardiometabolic clinical program. Incubated by Third Rock Ventures, the #biotech will use the money to fund phase 2 activities for lead program MAR001, a monoclonal antibody (#mAb) designed to inhibit ANGPTL4, a protein highly expressed in body fat. Preclinical models found that MAR001 reduced triglycerides, remnant cholesterol and ectopic fat, while improving insulin sensitivity. The biotech plans to launch a phase 2b trial assessing MAR001 for #metabolic dysfunction in the beginning of next year. Iambic Therapeutics (San Diego) has now raised an oversubscribed $50 million extension round led by new investors Mubadala Capital and Exor Ventures. The new cash will be used to advance the biotech's #clinical and #preclinical pipeline. This includes IAM1363, a small molecule inhibitor designed to treat both wild-type and oncogenic HER2 mutants currently in phase 1/1b testing, as well as a preclinical dual CDK2/4 inhibitor designed to tackle treatment resistance in solid tumors. āshibio, Inc (Brisbane) exited stealth mode today with $40 million in seed and Series A financing to advance therapies for bone and connective tissue disorders. MPM BioImpact led the Series A round, with contributing funds from Agent Capital, YK Bioventures, and Mirae Asset Capital Life Science. Recent Layoffs:  eFFECTOR Therapeutics, Inc. (Solana Beach): The #oncology biotech has laid off staff as it plans to wind down. This includes eFFECTOR CEO Stephen Worland, Ph.D.; CFO Michael Byrnes; and CMO Douglas Warner, M.D., who all stopped serving in their positions at the end of last week. M&A, Deals, Partnerships: Belharra Therapeutics (San Mateo & San Diego), a next-generation #chemoproteomics company transforming small molecule drug discovery by illuminating binding pockets on elusive, high-value drug targets across the proteome, announced a strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for #immunological diseases. FDA Approvals: Halozyme, Inc. (San Diego) announced that argenx received U.S. FDA approval for VYVGART® Hytrulo co-formulated with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20, for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (#CIDP). Adicet Bio, Inc (Redwood City) announced that the U.S. FDA has cleared the Company’s IND application to evaluate ADI-270, an armored allogeneic “off-the-shelf” gamma delta chimeric antigen receptor (CAR) T cell therapy candidate targeting CD70+ #cancers, for the treatment of relapsed/refractory renal cell #carcinoma (RCC). 4D Molecular Therapeutics (SF) announced U.S. FDA clearance of the IND for 4D-175, an R100 vector-based intravitreal #genetic medicine, for the treatment of patients with geographic atrophy.

💲Notable RNA deals in March and April 💲 These deals underscore the significance of RNA therapeutics and the delivery systems that ensure their precise targeting and efficacy. Headlined by the acquisition of Cardior Pharmaceuticals by Novo Nordisk for $1.1b USD. Cardior Pharmaceutical technology specializes in targeting abnormal levels of microRNA. Capstan Therapeutics raised an impressive $175m in their oversubscribed Series B. Capstan Therapeutics is looking to advance their CAR-T cell candidate and their targeted LNP pipelines. Regulus Therapeutics recently announced an oversubscribed $100m private placement of equity. They are focused on their pipeline candidates which target microRNAs. Orgenesis Inc. secured a $2.3m private investment and is expected to secure further payments. Orgenesis is a biotech focused on cell and gene therapies, aiming to provide affordable healthcare to patients. ----- Century Therapeutics, Inc raised $60m in private investments and used these funds to acquire Clade Therapeutics. With this move, Century adds to their allogeneic cell therapies. TuHURA Biosciences, Inc. received $31m subscribed financing and have entered into a definitive merger agreement with Kintara Therapeutics, Inc. NASDAQ: KTRA. GenEditBio Limited recently announced their $10m USD Pre-A+ funding round, their third funding round since 2021. The additional funds will be used to further their genome-editing technology platforms, e.g. LNPs and ePDVs. ARCA biopharma and Oruka Therapeutics announced their merger agreement earlier this month. They will look to advance Oruka's pipeline of potentially best-in-class biologics for the treatment of chronic skin diseases. ----- Deals pulled from Beacon Intelligence database. 🌟 Enjoying my content? Repost and follow Michael Hai Luu Nguyen, Ph.D. & Helix Biotech, Inc. for more! 🌟 #RNA #mRNA #RNAtherapeutics #LNPs #LNP #Helixbiotech #investors #deals #funding #biotech #pharma

What are Wave 3 biologics and why are they attracting little to no biosimilar competition? Wave 3 biologics are the latest wave of complex biologics characterized by rising levels of manufacturing, clinical testing and logistical complexity. This cohort comprises antibody-drug conjugates (ADC), cell and gene therapies (or Advanced Therapy Medicinal Products; ATMPs), oligonucleotides and PD-1 inhibitors. Wave 3 includes products facing LoE (loss of exclusivity) events by 2032. Although not all of these products target rare diseases, a rising share of them do. There are currently no candidates for any of these complex orphan drugs, but there are 16 candidates for non-orphan, Wave 3 biologics. The chart shows the pipeline for these biologics, which includes an early asset (Phase I) referencing trastuzumab emtansine, eight biosimilar candidates for pembolizumab and seven for nivolumab. Yet, not all these candidates are expected to progress to clinical trials or enter the European market following the expiry of patents and other exclusivity rights because of challenges to development and feasibility. IQVIA Institute’s Assessing the Biosimilars Void report further discusses the factors that affect the development and launch of new biosimilars for these complex biologics. Download the report here: https://bit.ly/46DMeZp. #GlobalHealth #Datascience #Biosimilars

InduPro Announces $85M Series A Financing https://lnkd.in/dHZJ3itc InduPro, Inc. , a biotechnology company defining protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced an $85 million Series A financing co-led by The Column Group and Vida Ventures with participation from investors, including MRL Ventures Fund (the therapeutics-focused venture fund of Merck & Co, Inc.), Emerson Collective and Euclidean Capital. The financing will support the advancement of the first expected clinical product candidate targeting cancer tissue based on the proximity of co-targeted pairs, from preclinical development to an expected IND filing in Q4 2025 for a Phase 1 clinical trial. It will also fuel a pipeline of novel bispecific antibodies and antibody drug conjugates (ADCs) that utilizes protein proximity for identification of novel tumor selective target pairings. Prakash Raman, Ph.D. joins as Chief Executive Officer of InduPro with more than two decades of biopharmaceutical business development and executive leadership experience, blending his… Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks

🚀🔬 It’s time to take a look at the biggest private biotech investments of July 2024! 💰 Last month, the companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest investment rounds. 🎯 And, just as in June, oncology and central nervous system players attracted the biggest funding rounds overall. 🧠💉 📍Plus, in terms of location, North America and Europe also achieved the same amount of fundraising rounds as they did in June, with 15 and 11 respectively. 🌍💼 Read our latest article to find out more details! 🔍 https://lnkd.in/d4xze2x7 #biotech #investments #pharma #oncology #innovation #funding #biotech2024 #healthcare CatalYm GmbH | Scorpion Therapeutics | NGM Biopharmaceuticals | Myricx Bio | Asceneuron SA | Autobahn Therapeutics, Inc. | SciRhom | Confo Therapeutics | GRO Biosciences | AIRNA | SmartCella Holding AB | AusperBio | Rona Therapeutics | CellCentric | ReviR Therapeutics | LTZ Therapeutics

Get our new application note today: 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗼𝗳 𝗢𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 https://okt.to/S9rJDn This application note reviews promising lipid conjugation techniques and nanocarriers in preclinical development as well as approved oligonucleotide therapeutics. Download it to learn more. #AppNote #oligonucleotide #ResearchChemicals #ScienceForASaferWorld